Product Name: Bmf Antibody
Species Reactivity: Human
Tested Applications: ELISA, IF, IHC-P, WB
Applications: Bmf antibody can be used for detection of Bmf by Western blot at 2.5 and 5 μg/mL. A band at approximately 25 kDa can be detected. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 10 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 25 kDa
Immunogen: Bmf antibody was raised with a synthetic peptide corresponding to 14 amino acids near the carboxy terminus of human Bmf.The immunogen is located within the last 50 amino acids of Bmf.
Host Species: Rabbit
Purification: Bmf Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 16485-10-2
Product: DL-Panthenol
Buffer: Bmf Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: Bmf antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Bmf Antibody: Bcl-2-modifying factor
Accession NO.: NP_277038
Protein Ino: 15723378
Official Symbol: BMF
Geneid: 90427
Background: Bmf Antibody: Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor). The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cells actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program. Bmf is constitutively expressed in many tissues.
PubMed ID:http://aac.asm.org/content/42/3/606.abstract
